PARK2 loss promotes cancer progression via redox-mediated inactivation of PTEN.
MetadataShow full item record
Cancer and Parkinson disease (PD) derive from distinct alterations in cellular processes, yet there are pathogenic mutations that are unequivocally linked to both diseases. Here we expand on our recent findings that loss of parkin RBR E3 ubiquitin protein ligase (PRKN, best known as PARK2)-which is genetically linked to PD-promotes cancer progression via redox-mediated inactivation of phosphatase and tensin homolog (PTEN) by S-nitrosylation.
Signalling & Cancer Metabolism
License start date
Molecular & cellular oncology, 2017, 4 (6), pp. e1329692 - ?